Kornimate/medical-research-clean huggingface dataset:
effect of opposite leg position on hamstring flexibility in patients with mechanical low back pain

Conditions: Flexibility

Summary: purpose: this study aimed to investigate the effect of opposite knee position on hamstring flexibility background hamstrings tightness is one of the most common findings in patients with lbp. it is thought that, due to the attachments of hamstrings to the ischial tuberosity, hamstrings tightness generates posterior pelvic tilt and decreases lumbar lordosis, which can result in lbp. hypotheses there will be significant difference in the hamstring flexibility with changing position of opposite knee (flexed or extended) in patients with mechanical low back pain. research question: will changing position of opposite knee (flexed or extended) affect the hamstring flexibility in patients with mechanical low back pain?

* the subject will be instructed to maintain 90° hip flexion in the supine position. * then asked to actively extend the knee joint. * the degree of achieving active knee extension will be measured using a universal goniometer. * the average of three active knee extension measurements will be recorded used as the hamstring muscle length for the data analysis (dong-kyu lee, et al., 2018). * this test will be done for the same limb with opposite leg extended and with opposite flexed.

Eligibility criteria:
inclusion criteria: * patients with history of back pain and assessed with mechanical inflammatory low back pain index and have very high grade for mechanical component. * age ranges from 18-40 years. * the body mass index of the subject is ≤25 kg/meter square. exclusion criteria: 1. previous trauma, fractures or surgery of the back. 2. malignancy of the back. 3. rheumatoid arthritis 4. spondylolysis or spondylolithesis 5. history of lower extremity injury within 6 months prior to the study
further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk open-label extension

Conditions: Dyslipidemia

Summary: the primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (cvd).

this is a multicenter, open-label extension study designed to assess the long-term safety of evolocumab in subjects who completed the fourier study,which is a randomized placebo-controlled study of evolocumab in subjects with clinically evident atherosclerotic cvd on stable effective statin therapy. eligible subjects at sites participating in fourier ole who have signed the fourier ole informed consent may be enrolled at the completion of fourier study.

Eligibility criteria:
inclusion criteria: * subject has provided informed consent before initiation of any study-specific activities/procedures * subject has completed fourier (study 20110118) while still receiving assigned investigational product. exclusion criteria: * investigational product was permanently discontinued during fourier for any reason, including an adverse event or serious adverse event * subject is currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(ies) within less than 4 weeks. other investigational procedures while participating in this study are excluded * subject is not likely to be available to complete protocol-required study visits or procedures and/or to comply with required study procedures to the best of the subject's and investigator's knowledge * subject has a history or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion * subject has a known sensitivity to any of the active substances or excipients (eg, sodium acetate) to be administered during dosing * female subject is pregnant or breastfeeding or is planning to become pregnant or planning to breastfeed during treatment with evolocumab and within 15 weeks after the end of treatment with evolocumab * female subjects of childbearing potential who are not willing to use an acceptable method(s) of effective birth control during treatment with evolocumab and for an additional 15 weeks after the end of treatment with evolocumab are excluded

Keywords: high cholesterol treatment for high cholesterol lowering cholesterol lowering high cholesterol hypercholesterolemia
community pharmacists behaviour during covid-19

Conditions: Covid19

Summary: during the covid-19 pandemic, governments issued movement restrictions and placed areas into quarantine to reduce the spread of the disease.community pharmacists and their teams are a vital healthcare provider during the outbreak; they remain on the frontline of public health by serving as direct points of access for their patients. the retail pharmacists should provide public community, costumers and patients with right and trusted information about covid-19. they also should have role in awareness spreading regarding personnel safety and hygiene

the survey will enroll as many community pharmacists as possible in the survey portion of the study - the number of participates have no limitations, at least 50 participants. the survey will be enrolled in online google form, face to face interview \& semi-structured telephone interviews if possible. the research procedures: 1. an online survey link will include questions regarding the impact of role and behavior of retail pharmacists during covid-19 outbreak. 2. face to face and semi-structured interviews if possible: for those pharmacists who state that they would like to participate in an interview, a random sample will be contacted. inclusion criteria: 1. post graduated pharmacist. 2. community pharmacists. exclusion criteria: 1. under graduated students. 2. not pharmacist.

Eligibility criteria:
inclusion criteria: * post graduated pharmacist. community pharmacists. exclusion criteria: * under graduated students. not pharmacist.

Keywords: pharmacists/ covid-19
efficacy and safety of a probiotic product in children with antibiotic-associated gastrointestinal disorders.

Conditions: Antibiotic-associated Loose/Watery Stools

Summary: to assess the tolerability and effect of a probiotic product, when co-administered with antibiotics, on the incidence and duration of loose/watery stools following the antibiotic treatment in children.


Eligibility criteria:
inclusion criteria 1. children at the age of 1-11 years that have been ordinated to start antibiotic treatment except for penicillin. 2. possibility to initiate the probiotic treatment within 24 hours after the first dose of the antibiotic treatment. 3. children whose parents or legal caregivers have signed the informed consent to participate in the study. exclusion criteria 1. chronic intestinal disease. 2. current immunodeficiency or immunosuppressive treatment. 3. chronic or acute diarrhoeal disease. 4. use of laxatives the week before inclusion in the study. 5. antibiotic treatment for the last four weeks before inclusion in the study. 6. known hypersensitivity to any of the ingredients in the probiotic product or the placebo \[potato starch, silicon dioxide, capsule (hypromellose, water) ± bacterial culture\]. 7. intake of any probiotic products for the last two weeks before inclusion in the study. 8. patient requiring hospitalisation. lack of parents´/legal guardians´ informed consent.
position of egd in droplet spreading

Conditions: Cotamination on Face Shield

Summary: the association between position of upper gastrointestinal endoscopy (egd) and saliva droplet spreading has never been studied. in the era of contagious viral spreading, this pilot study is aimed to assess adenosine triphosphate (atp) at the face shield of endoscopist which can represent the saliva droplet spreading of patients in left lateral and prone position during egd.


Eligibility criteria:
inclusion criteria: * patients who have the indication for upper gastrointestinal endoscopy exclusion criteria: * cannot be in prone position * the endoscopist deny the assigned position in any reason.
study to compare the use of a behavioral health app versus care as usual for 16-22 year olds with depression

Conditions: Depression

Summary: randomized controlled trial comparing a coach-enhanced digital cognitive behavioral intervention (d-cbi) (rxwell) + treatment as usual (tau) versus tau alone for moderate depression as determined by patient health questionnaire (phq-9) threshold as part of routine pediatric care. the study will be completed in pediatric practices with embedded behavioral therapists across 3 institutions (children's hospital of pittsburgh, boston children's hospital, rady children's hospital, san diego).

after consent, participants will be further screened to determine eligibility. they will complete a brief structured clinical interview for diagnostic and statistical manual of mental disorders, fifth edition (dsm5) (scid). if someone has been hospitalized in the past 3 months for dangerousness, or is diagnosed with severe current psychiatric disorders based on scid v (clinical trials version) for bipolar disorder, current substance misuse or dependence, or thought disorder they will not be eligible for this study and will be referred back to the clinician for further support. participant procedures: all participants who are eligible for this study, consent to participate, and are randomized to one of the two arms (dcbi+tau or tau) will be asked to complete self-report and blinded clinician administered measures on three occasions over 12 weeks (baseline, 6-, and 12-week time points). at enrollment and prior to randomization, each participant will be assigned a unique study id that will be used to code all data collected for research purposes. participants will be asked to complete self-report assessments via 1) self-administered completion of assessments through redcap cloud (i.e., online); 2) over the phone with a member of the research team who will enter the participant's responses into a secure web-based portal (redcap cloud).

Eligibility criteria:
inclusion criteria: * age 16-22 inclusive recruited from outpatient pediatric clinic visit. * meeting positive screen criteria depression by phq-9 criteria (score greater than or equal to10). * english-speaking (participant) * smart phone access exclusion criteria: * extremely severe depression (phq-9 greater than 24; or active suicidal plan). * current dangerousness (based on treatment for adolescents for depression study (tads) study criteria, 2004). hospitalized for dangerousness within 3 months; suicide attempt requiring medical attention within 3 months. * severe, current psychiatric disorders based on scid v (clinical trials version) for bipolar disorder, current substance misuse or dependence, thought disorder. research coordinators who are trained to fidelity threshold will complete this measure with the patient.

Keywords: mobile app digital behavioral tool adolescent and young adult
study to assess sln124 in patients with polycythemia vera

Conditions: Polycythemia Vera

Summary: this is a phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of sln124 in adult patients with polycythemia vera (pv) to assess the safety, tolerability, efficacy, pharmacokinetic (pk), and pharmacodynamic (pd) response of sln124.


Eligibility criteria:
inclusion criteria: * male and female patients aged 18 years or older. * a confirmed diagnosis of pv according to the revised 2016 world health organization criteria: * suitable phlebotomy history * must agree to adhere to appropriate contraception requirements * patients who are not receiving cytoreductive therapy must have been discontinued from any prior cytoreductive therapy for at least 24 weeks before dosing and have recovered from any adverse events due to cytoreductive therapy. * patients receiving cytoreductive therapy with hydroxyurea, interferon, busulfan or ruxolitinib must have received a stable dose of cytoreductive therapy for at least 12 weeks before dosing and with no planned change in dose. * patients must have had a dermatological examination within 6 months prior to screening. * must have an eastern cooperative oncology group score of 0, 1, or 2. exclusion criteria: * drug intolerance: 1. history of intolerance to oligonucleotides, or galnac, or any component of sln124. 2. history of intolerance to s.c. injections. * clinically significant thrombosis (e.g., deep vein thrombosis or splenic vein thrombosis) within 12 weeks of screening. * history of major bleeding events and/or a requirement for blood transfusion therapy owing to bleeding in the last 6 months prior to screening. * meets the criteria for post-pv myelofibrosis as defined by the international working group-myeloproliferative neoplasms research and treatment * any investigational drug less than 6 weeks prior to the first dose of study drug or not recovered from effects of prior administration of any investigational agent. * any investigational or marketed product using galnac targeting less than 48 weeks prior to administration of any investigational agent. * clinically significant co-morbidities * biochemical and hematological parameters: 1. biochemical evidence of significant liver disease during screening 2. hematological parameters at screening as follows: platelets 1,000,000/µl; or white blood cell (wbc) count \> 25,000/µl; or peripheral blasts \< 1%.

Keywords: pv
audit of tolerability and safety of acute pain service

Conditions: Acute Pain

Summary: acute pain service (aps) was introduced in 1990s at queen mary hospital (qmh) as other countries. with accumulation of experience and clinical evidence, aps has been well established. a study conducted in 1997 suggested that monitoring, management protocol and nursing experience were mandatory to the safety for aps. our recent study showed that pain relief of our post-operative patients using patient controlled analgesic with morphine was still not adequate. the results has driven us to continue the improvement of post-operative outcomes for our surgical patients. tolerability and safety are always our concerns for patients using our aps. therefore, the investigators aim to conduct this retrospective study in order to assess if the tolerability and safety of our present aps are adequate or not. the study results will help us to further improve our aps at qmh if necessary.

retrospective audit. acute pain service records at division of pain management, department of anaesthesiology, queen mary hospital will be identified, validated and analysed. data collection 1. demographic data 2. type of operation 3. type of pain relief modality 4. pain score up to 72 hours postoperatively 5. types of operations and clinical variables 6. incidence of adverse events during aps care; 7. patients safety (ie respiratory depression) data analysis for summarising analysis, mean or median with standard deviation or interquartile range will be reported. parametric and non-parametric comparative tests will be used for analysis between/among patients with various characteristics. kaplan meier survival analysis and log-rank test will be used for duration of aps use.

Eligibility criteria:
inclusion criteria: * postoperative patients who were cared by the acute pain service, pain management team, department of anaesthesiology, queen mary hospital between 2009 to 2012. exclusion criteria: * essential data were missing; * patient participating in other research projects.

Keywords: acute pain audit safety tolerability
an appearance-based intervention to reduce teen skin cancer risk

Conditions: Skin Cancer

Summary: the purpose of this study is to determine whether a skin cancer prevention website is effective at reduce female teenagers' desire to use indoor tanning and ultimately their use of indoor tanning over an 18 month period.

the project is designed to improve the understanding of, and ability to affect uv risk behavior in teenage populations. the international agency for research in cancer classifies indoor tanning as "carcinogenic to humans." there is evidence that female indoor tanning use increases dramatically from freshman to senior years of high school (e.g., 25-40% of older high school girls) making high school a critical time period for anti-tanning interventions to be carried out. this proposal assesses the effectiveness of a skin cancer prevention website for a nationally representative sample of high school teens in a randomized controlled trial. teens exposed to the website will report reduced indoor tanning intentions, frequency and overall percentage of users while increasing sun protective behaviors at long-term (i.e 18 month) follow-up.

Eligibility criteria:
inclusion criteria: * teenager between 12 and 18 years old; has either indoor tanned in the past year or has indicated their intentions to indoor tan in the coming year. exclusion criteria: * none other than not meeting inclusion criteria.

Keywords: melanoma basal cell carcinoma squamous cell carcinoma
edentulous maxilla opposed by 2-implant mandibular overdenture?

Conditions: Prosthesis Durability

Summary: this within -subject study will be conducted to evaluate the proper number of unsplinted implants ;( three, four and five implants) for the edentulous maxilla opposed by mandibular two-implant overdentures.


Eligibility criteria:
inclusion criteria: * o healthy and free from any systemic diseases that may interfere with the osseointegration of implants. * patients have completely edentulous maxilla for at least 6 months after last extraction with opposing mandibular two-implant overdentures. * the patients have angle class i maxillomandibular skeletal relation and sufficient interarch space not less than (10-12 mm) as detected by tentative jaw relation. * maxillary and mandibular alveolar ridges covered with healthy, firm, relatively even thickness and even compressible mucosa as detected by palpation with the blunt end of the mirror and free from any signs of inflammation or flabbiness as detected by clinical examination. * good quality and quantity of maxillary residual alveolar ridge, as detected by cbct, available for implant width (3.7mm, 5mm for anterior and posterior implants respectively) and length (12mm, 10mm for anterior and posterior implants respectively) this was ascertained by cbct. exclusion criteria: * o any history of metabolic or systemic diseases that may affect integration of implant or connective tissue health surrounding implant. * history of irradiation in head-and-neck area. * heavy smokers (more than 10 cigarettes per day) * parafunctional habits such as bruxism. * psychiatric disorders or unrealistic expectations. * positive pregnancy test up to 5 days before surgery. * severe thrombocytopenia and bleeding disorders. * pathologic condition of soft tissue (bacterial and viral stomatitis, hyperplasia, cyst, fibrous lesions) * patients with local contraindications for implant placement due to localized bone defects and poor bone quality (d5). * patients with tmj disorders or poor neuromuscular coordination.
inventory of the management of acute community-acquired pneumonia in strasbourg university hospitals

Conditions: Infection, Lung Parenchyma

Summary: acute community-acquired pneumonia (cap) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. it is a frequent, serious pathology with a strong economic impact. viruses (rhinovirus, respiratory syncitial virus, influenza virus for the most common) and streptococcus pneumoniae are the most frequently encountered pathogens. however, more than half of the pacs have no microbiological documentation. the management of caps is based on national and international recommendations. several studies have shown imperfect compliance by clinicians with recommendations with a prognostic impact. the various published studies insist on the variability of the incidence, the type of pathogen, the severity and the economic impact, depending on the series. they also insist on the need to know the local epidemiology, in particular microbiological, in order to adapt the recommendations.

the objective of the study is to determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia.

Eligibility criteria:
inclusion criteria: * adult subject (≥ 18 years old), * acute community-acquired pneumonia (\< 48 hours after admission), * admitted from the emergency department, consultation or home. * subject not objecting to the reuse of their data for scientific research purposes exclusion criteria: * expressed refusal to reuse data for scientific research purposes. * bronchitis, acute nosocomial pneumopathy, secondary infection due to bronchial dilation.

Keywords: community-acquired pneumonia infection, lung parenchyma rhinovirus respiratory syncitial virus influenza virus streptococcus pneumoniae
pandemic influenza plasmid dna vaccines (needle-free)

Conditions: Influenza

Summary: the trial will enroll up to 47 subjects. qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine. subjects will receive 2 vaccinations with the biojector® 2000, and will be followed for 6 months to evaluate the safety of and the immune system's response to the vaccine. the safety and immune system's response will be studied throughout the trial.


Eligibility criteria:
inclusion criteria: * 18 to 45 years of age * able to provide informed consent and be followed for 6 months exclusion criteria: * no immunomodulatory therapy within the past 6 months * no evidence of immunodeficiency or pregnancy * no laboratory or evidence of clinically significant medical disease * no history of previous pdna immunization * no influenza immunization within the past 30 days * no blood donations within 30 days of screening visit * no history of bleeding disorder * no use of aspirin and/or anticoagulants within 2 weeks of the administration of the investigational vaccines

Keywords: pandemic influenza avian influenza dna vaccines antibody t cells ha/np/m2 biojector